A
Atsushi Ohtsu
Researcher at Juntendo University
Publications - 468
Citations - 32146
Atsushi Ohtsu is an academic researcher from Juntendo University. The author has contributed to research in topics: Cancer & Chemoradiotherapy. The author has an hindex of 72, co-authored 457 publications receiving 27396 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang Cheul Oh,György Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer A. Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D. Schwartz,Atsushi Ohtsu +19 more
TL;DR: The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Journal ArticleDOI
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio Garcia-Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Eveline Boucher,Marc Peeters,Ben Tran,Heinz-Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu +23 more
TL;DR: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival, and this phase 3 trial was the first to report this result.
Journal ArticleDOI
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu,Manish A. Shah,Eric Van Cutsem,Sun Young Rha,Akira Sawaki,Sook Ryun Park,Ho Yeong Lim,Yasuhide Yamada,Jian Wu,B. Langer,Michal Starnawski,Yoon-Koo Kang +11 more
TL;DR: The Avastin in Gastric Cancer (AVAGAST) trial as discussed by the authors evaluated the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer.